Financial Performance - The company generated a net income of $5.3 million for the year ended December 31, 2022, primarily due to revenues from royalties and milestone payments [185]. - For the years ending December 31, 2025 and 2024, the company incurred net losses of $66.5 million and $61.2 million, respectively, with an accumulated deficit of $304.1 million as of December 31, 2025 [185]. - The company does not expect to achieve profitability or positive cash flows from operations in the foreseeable future [185]. - The company has incurred significant losses since inception and expects to continue incurring losses for at least the next several years [184]. - The company has not yet generated any material revenue from its current product candidates and does not expect significant revenue until successful commercialization [189]. - As of December 31, 2025, the company had cash, cash equivalents, and restricted cash of $71.9 million, which is expected to support operations for at least the next 12 months without additional financing [199]. Business Transactions and Shareholder Structure - Following the completion of the contemplated transactions, current shareholders are expected to own approximately 34% of the outstanding shares of Topco, while former Clywedog stockholders are expected to own approximately 66% [178]. - The anticipated closing of the contemplated transactions is expected in the second quarter of 2026, subject to various conditions being satisfied [170]. Operational Risks and Challenges - The integration of operations with Clywedog may result in unanticipated problems and expenses, potentially harming financial performance [174]. - The company is subject to restrictions on business activities under the Merger Agreement, limiting its ability to take certain actions without prior consent from Clywedog [183]. - The company anticipates substantial increases in expenses as it pursues clinical development and expands operational capabilities [186]. - The company faces significant translational risk as promising preclinical results may not be replicated in clinical trials, impacting revenue generation [190]. - The company may face challenges in accessing new capital due to recent volatility in capital markets, which could limit growth and operational capabilities [209]. - The company faces significant risks related to access to funding sources, which could be impaired by liquidity constraints or disruptions in the financial services industry [211]. Clinical Development and Regulatory Risks - The company is in the preclinical stages of development for certain product candidates, which will require substantial investment and additional clinical development before generating revenue [190]. - The company has not yet demonstrated the ability to successfully complete clinical trials beyond Phase 2b or obtain marketing approvals [194]. - The company expects research and development expenses to increase as it continues preclinical and clinical development activities [204]. - The company may face increased costs and delays if clinical trials do not proceed as planned, impacting overall financial condition [228]. - Delays in clinical trials or regulatory approvals could significantly harm the commercial prospects of product candidates and delay revenue generation [226]. - Regulatory authorities may not accept the company’s assumptions or analyses, potentially impacting the approval and commercialization of product candidates [230]. Market and Competitive Landscape - The company faces substantial competition from various sources, including major pharmaceuticals and biotechnology companies, which may hinder its ability to successfully market or commercialize its product candidates [248]. - The company’s lead product candidate, VTP-1000, is in early development stages and requires extensive clinical testing, with revenue generation expected to be several years away [217]. - The company anticipates that the market opportunities for certain product candidates may be limited to patients who are ineligible for or have failed prior treatments, potentially affecting profitability [240]. Manufacturing and Supply Chain Risks - The company does not currently own manufacturing facilities and relies on third-party manufacturers, which poses risks related to quality and supply [279]. - Reliance on a limited number of third-party manufacturers exposes the company to risks, including geopolitical developments affecting supply chains, particularly with China-based suppliers [282]. - The production process for product candidates requires specific know-how, and competition for manufacturing capacity may hinder the ability to secure sufficient resources [283]. Taxation and Financial Regulations - As of December 31, 2025, the company had cumulative carryforward tax losses of approximately $160.4 million, up from $101.7 million as of December 31, 2024 [311]. - The company expects to benefit from the U.K. research and development tax credit regime starting in 2025, with a Research and Development expenditure credit rate of 20% [312]. - The U.K. tax authority has increased scrutiny on claims for R&D tax credits, which may affect the company's ability to utilize such credits in the future [316]. Data Protection and Compliance Risks - The company faces risks related to data protection and privacy laws, particularly the GDPR, which imposes strict obligations on personal data processing [340]. - Non-compliance with GDPR could lead to substantial fines and restrictions on business activities outside Europe [343]. - The company has implemented measures to comply with GDPR, but ongoing compliance remains resource-intensive and challenging [344]. Intellectual Property Risks - The patent prosecution process is expensive and complex, with uncertainties regarding the issuance and scope of patents that could impact the company's competitive position [362]. - The biotechnology and pharmaceutical patent landscape is highly uncertain, with pending applications not guaranteed to result in enforceable patents [363]. - The company relies heavily on licenses from third parties for essential patent rights and proprietary technology, which imposes various obligations that must be met to maintain these licenses [366].

Core Insights - Barinthus Biotherapeutics plc reported its financial results for the year ended December 31, 2025, highlighting a strategic focus on immunology and inflammation therapies, particularly VTP-1000 for celiac disease [1][2][6]. Financial Performance - Total research and development expenses decreased to $25.6 million in 2025 from $42.2 million in 2024, primarily due to reduced activity in legacy asset clinical programs [10][23]. - General and administrative expenses rose to $40.8 million in 2025, up from $29.7 million in 2024, reflecting increased professional fees and other costs [10][23]. - The company reported a net loss of $66.5 million for 2025, compared to a net loss of $61.1 million in 2024, resulting in a loss per share of $(1.64) [14][23]. Corporate Developments - Barinthus Bio is in the process of merging with Clywedog Therapeutics, expected to complete in the second quarter of 2026, creating a company focused on metabolic and autoimmune diseases [5][7]. - The merger will result in the combined entity being renamed "Clywedog Therapeutics Holdings, Inc." and trading under the ticker symbol "CLYD" [7]. - The single ascending dose portion of the Phase 1 AVALON trial for VTP-1000 was completed, with positive results indicating good tolerance and immune response in celiac disease patients [6][10]. Upcoming Milestones - Data from the multiple ascending dose portion of the Phase 1 AVALON clinical trial for VTP-1000 is anticipated in the second half of 2026, which includes a gluten challenge following three doses of the test medication [4][5]. - The merger with Clywedog is expected to enhance the clinical pipeline and attract high-caliber institutional investors [5][7].

Barinthus Biotherapeutics Corporate Presentation Guiding the Immune System to Cure Disease March 2026 Nasdaq: BRNS Disclosure Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Clywedog and Barinthus Bio, in light of h ...

Core Viewpoint - Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Barinthus Biotherapeutics signifies an improvement in the company's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the tracking of earnings estimate revisions a valuable investment strategy [5][7]. - Barinthus Biotherapeutics has seen a 1.1% increase in the Zacks Consensus Estimate over the past three months, indicating a positive trend in earnings expectations [9]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The upgrade to Zacks Rank 2 places Barinthus Biotherapeutics in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10][11].

Core Insights - Barinthus Biotherapeutics plc announced positive results from the Phase 1 trial of VTP-1000 for celiac disease, showing it was well tolerated with no serious adverse events and a dose-dependent pharmacological effect [1][2][6] Company Overview - Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for autoimmune and inflammatory diseases, utilizing its proprietary SNAP-TI platform [5][7] - The company's lead candidate, VTP-1000, aims to restore immune non-responsiveness to gluten in celiac disease patients and is currently in a Phase 1 clinical trial [5][6] Trial Details - The single ascending dose (SAD) portion of the AVALON trial enrolled 18 patients across three placebo-controlled cohorts, demonstrating that VTP-1000 was well tolerated at all dose levels [2][6] - The multiple ascending dose (MAD) portion of the trial, which includes a gluten challenge, is ongoing with results expected in the second half of 2026 [1][6] Disease Context - Celiac disease affects approximately 1 in 100 people globally, leading to an autoimmune response to gluten that can cause significant health issues [4] - There are currently no approved treatments for celiac disease, making the development of VTP-1000 particularly significant [4]

Financial Performance - For the three and nine months ended September 30, 2025, the company incurred a net loss of $14.6 million and $55.4 million, respectively, with an accumulated deficit of $293.0 million as of September 30, 2025[110]. - Net loss for the nine months ended September 30, 2025 was $55.4 million, compared to a net loss of $40.6 million in 2024, an increase of $14.8 million[169]. - Cash used in operating activities was $43.7 million for the nine months ended September 30, 2025, compared to $42.0 million in 2024, an increase of $1.7 million[169]. - The company has incurred losses in each year since its inception in 2016, except for 2022 when it was profitable[175]. - The company expects to continue incurring net negative cash flows from operations for at least the next few years as it progresses clinical development[166]. - As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $75.7 million[162]. - As of September 30, 2025, the company had an accumulated deficit of $293.0 million and expects to continue incurring significant losses and negative cash flows from operations for the foreseeable future[175]. Research and Development - The company is currently conducting a Phase 1 clinical trial for its lead candidate VTP-1000, aimed at restoring immune non-responsiveness to gluten in celiac disease patients, with data expected before the end of 2025[115]. - The ongoing development of VTP-300, a Phase 2 immunotherapeutic treatment for chronic hepatitis B, is being pursued with the intention of finding a partner for continued development[108]. - The company has incurred significant research and development expenses, which are expected to increase as it progresses its programs through the next stages of development[124]. - Research and development expenses decreased to $5.39 million in Q3 2025 from $11.14 million in Q3 2024, a reduction of $5.75 million[143]. - Research and development expenses totaled $21.6 million for the nine months ended September 30, 2025, down from $33.9 million in 2024, a decrease of $12.3 million[153]. Mergers and Acquisitions - The company has entered into a merger agreement with Topco and Clywedog, which is expected to close in the first half of 2026, resulting in the company becoming a wholly owned subsidiary of Topco[116]. - The combined company will focus on advancing a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases, with four clinical data milestones anticipated within 18 months post-merger[120]. - The company entered into a definitive merger agreement with Clywedog, which triggered an impairment assessment due to the indicative offer price being below the fair value of net assets[139]. - On September 29, 2025, the company entered into a merger agreement with Clywedog, agreeing to conduct business in the ordinary course until the merger closes[167]. Operating Expenses - Total operating expenses for the quarter were $15.22 million, down from $24.56 million in 2024, reflecting a decrease of $9.34 million[141]. - Total operating expenses decreased to $59.5 million for the nine months ended September 30, 2025, down from $60.5 million in 2024, a reduction of $1.1 million[151]. - General and administrative expenses decreased to $5.17 million in Q3 2025 from $13.42 million in Q3 2024, a decrease of $8.25 million[146]. - General and administrative expenses increased to $33.2 million for the nine months ended September 30, 2025, up from $26.6 million in 2024, an increase of $6.6 million[156]. - The company recorded an impairment charge of $4.67 million for long-lived assets in Q3 2025, compared to no impairment in Q3 2024[147]. - Impairment of long-lived assets was $4.7 million for the nine months ended September 30, 2025, compared to nil in 2024[158]. Financing and Capital Requirements - The company expects to finance future cash needs through public or private equity offerings, debt financings, collaborations, or licensing arrangements, as it does not anticipate positive cash flows from operations in the foreseeable future[112]. - The company anticipates that its existing cash and financial resources will fund its operating expenses into the start of 2027, based on current standalone research and development plans[112]. - Future capital requirements will depend on various factors, including the success of product candidates and the ability to generate revenue[180]. - The company may require substantial additional financing in the future to meet unanticipated factors and operational needs[182]. Tax and Regulatory Considerations - The company expects to benefit from the UK R&D tax credit regime, with a credit rate of 20% under the merged scheme for qualifying expenditures[131]. - The PAYE cap for claims under the merged scheme and ERIS is set at £20,000 plus 300% of the company's relevant PAYE and National Insurance contributions liabilities[130]. - The company anticipates that unsurrendered UK losses may be carried forward indefinitely to offset future taxable profits, subject to certain limitations[134]. Currency and Foreign Exchange Risks - A hypothetical 10% weakening of the U.S. dollar relative to the pound sterling would have materially affected current and projected expenses denominated in pound sterling[192]. - The company is subject to foreign currency exchange rate fluctuations, particularly with respect to the euro, pound sterling, Swiss franc, and Australian dollar[190]. - The company has significant operating costs in the United Kingdom, exposing it to changes in the exchange ratio of the U.S. dollar and the pound sterling[192]. - The company may need to relinquish valuable rights to technologies or future revenue streams if it raises additional funds through collaborations[183].

Financial Performance - The net loss for Q3 2025 was $14.6 million, or $(0.36) per share, compared to a net loss of $21.1 million, or $(0.52) per share in Q2 2025[8]. - For the three months ended September 30, 2025, total revenue was $0, compared to $15.0 million for the same period in 2024, indicating a decline of 100%[16]. - The net loss for the three months ended September 30, 2025, was $14.6 million, compared to a net loss of $8.1 million for the same period in 2024, representing an increase in loss of approximately 80.5%[16]. - The company reported a comprehensive loss of $17.5 million for the three months ended September 30, 2025, compared to a comprehensive gain of $1.1 million in the same period of 2024[16]. - The accumulated deficit increased to $293.0 million as of September 30, 2025, from $237.7 million at the end of 2024, reflecting a rise of about 23.3%[15]. Cash and Assets - As of September 30, 2025, Barinthus Bio reported cash, cash equivalents, and restricted cash of $75.7 million, down from $87.8 million as of June 30, 2025, reflecting a decrease of $12.1 million due to operating activities and currency translation losses[4]. - As of September 30, 2025, total assets decreased to $109.2 million from $160.3 million as of December 31, 2024, representing a decline of approximately 31.9%[15]. - Total current assets fell to $86.8 million, down from $125.7 million, a decrease of about 30.9%[15]. - Total liabilities decreased to $24.6 million from $30.2 million, a reduction of approximately 18.1%[15]. Research and Development - Research and development expenses for Q3 2025 were $5.4 million, a decrease of $2.6 million from $8.0 million in Q2 2025, attributed to reduced activity in infectious disease and oncology programs[7]. - Research and development expenses for the nine months ended September 30, 2025, totaled $21.6 million, down from $33.9 million in the prior year, a decrease of approximately 36.2%[16]. - The company is actively seeking partners to advance its VTP-300 program in chronic hepatitis B and VTP-850 program in prostate cancer[6]. Operating Expenses - Operating expenses for the three months ended September 30, 2025, were $15.2 million, down from $24.6 million in the prior year, a decrease of approximately 38.2%[16]. - General and administrative expenses decreased to $5.2 million in Q3 2025 from $15.4 million in Q2 2025, primarily due to reduced unrealized losses on foreign exchange[8]. - Impairment of long-lived assets expense was $4.7 million in Q3 2025, reflecting a valuation less than the carrying value of net assets due to the merger agreement[8]. Future Outlook - Barinthus Bio expects to fund its operating expenses and capital expenditures into 2027 based on its current resources[4]. - The company anticipates single ascending dose data readout for VTP-1000 before the end of 2025, with multiple ascending dose data expected in the second half of 2026[5]. - A definitive merger agreement was announced to combine with Clywedog Therapeutics, expected to close in the first half of 2026, creating a combined company with an estimated cash runway extending through 2027[6]. - The proposed combination with Clywedog aims to diversify the pipeline and broaden the base of institutional investors, targeting metabolic and autoimmune diseases[2].

Core Insights - Barinthus Biotherapeutics plc reported its financial results for Q3 2025, highlighting a net loss of $14.6 million, or $(0.36) per share, an improvement from a net loss of $21.1 million, or $(0.52) per share, in Q2 2025 [11][21] - The company announced a proposed merger with Clywedog Therapeutics, aiming to create a diversified portfolio targeting metabolic and autoimmune diseases, with the transaction expected to close in the first half of 2026 [2][6][7] Recent Corporate Developments - The merger with Clywedog is anticipated to strengthen Barinthus Bio's pipeline and broaden its investor base, with four clinical data milestones expected within 18 months post-transaction [6][7] - The company is actively seeking partners for its VTP-300 program in chronic hepatitis B and VTP-850 program in prostate cancer [7] Financial Highlights - As of September 30, 2025, Barinthus Bio had cash and cash equivalents of $75.7 million, down from $87.8 million as of June 30, 2025, primarily due to operating expenses [7][11] - Research and development expenses decreased to $5.4 million in Q3 2025 from $8.0 million in Q2 2025, attributed to reduced activity in infectious disease and oncology programs [8][11] - General and administrative expenses were $5.2 million for Q3 2025, significantly lower than $15.4 million in Q2 2025, mainly due to reduced unrealized losses on foreign exchange [11][21] Clinical Developments and Upcoming Milestones - The single ascending dose data readout for VTP-1000 is expected before the end of 2025, with enrollment in the multiple ascending dose part of the AVALON trial ongoing [6][7] - The company anticipates that research and development expenses related to autoimmune programs will continue at current levels or increase as clinical development progresses [8]

Core Insights - ChemDiv will continue to provide support to Clywedog Therapeutics as it merges with Barinthus Therapeutics, forming a new entity named Clywedog Therapeutics, Inc. The merger aims to advance clinical-stage candidates in Type 1 diabetes, Type 2 diabetes, and celiac disease [1][4]. Company Overview - ChemDiv is a global provider of integrated drug discovery solutions, offering a comprehensive range of services including medicinal chemistry, computational modeling, and clinical pharmacology support [7]. - Clywedog Therapeutics focuses on metabolic and autoimmune diseases, with key programs targeting Type 1 and Type 2 diabetes [6]. - Barinthus Biotherapeutics specializes in developing immunotherapeutics for autoimmune and inflammatory diseases, having rebranded from Vaccitech plc in 2023 [5]. Merger Details - The merger between Barinthus and Clywedog is expected to close in the first half of 2026, combining expertise in immunology and metabolic disease with three clinical-stage assets and multiple near-term data milestones [4]. - The new company will operate under the ticker CLYD on Nasdaq upon closing [1]. Collaborative Efforts - ChemDiv's collaboration with Clywedog includes accelerated CMC research, AI-enabled pharmacology, and translational biology, facilitating the transition of Clywedog's programs to clinical stages in 2023-2024 [2]. - The partnership has successfully advanced MENÂ PPI inhibitors and TYK2 inhibitors, which show promise in treating Type 2 and Type 1 diabetes, respectively [3].

Mergers and Acquisitions Overview - 89bio, Inc. will be acquired by Roche for $14.50 per share in cash, plus a contingent value right of up to $6.00 per share, with investigations into the Board's fiduciary duties regarding fair process and value [2] - Barinthus Biotherapeutics plc will merge with Clywedog Therapeutics, with Barinthus shareholders receiving one share of the new company for each ADS or ordinary share owned, and Clywedog shareholders receiving 4.358932 shares, raising questions about the Board's fiduciary duties [4] - Dayforce, Inc. is set to be acquired by Thoma Bravo for $70.00 per share in cash, with an enterprise value of $12.3 billion, while investigations focus on whether the deal consideration is fair compared to the 52-week high of $82.69 [6] - Verint Systems Inc. will also be acquired by Thoma Bravo for $20.50 per share, with investigations into the Board's fiduciary duties and the deal's fairness compared to the 52-week high of $34.80 [8]